Argonaute RNA Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.43M

  • Investors
  • 9

Argonaute RNA General Information

Description

Developer of bispecific siRNA therapeutics designed to address cardiometabolic diseases through targeted gene silencing. The company's therapeutics use proprietary stabilization technology and dual-siRNA chemistry to silence two target genes from a single molecule, enabling pharmaceutical partners to develop treatments for complex cardiometabolic diseases where simultaneous gene silencing may address residual disease risk.

Contact Information

Website
www.argonauterna.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Cardiff Business Technology Centre
  • Senghennydd Road
  • Cardiff CF24 4AY
  • Wales, United Kingdom
+44 0117
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Cardiff Business Technology Centre
  • Senghennydd Road
  • Cardiff CF24 4AY
  • Wales, United Kingdom
+44 0117

Argonaute RNA Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Argonaute RNA Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 24-Sep-2026 $2.43M Completed Generating Revenue
5. Accelerator/Incubator Completed Pre-Clinical Trials
4. Later Stage VC 17-Jul-2024 Completed Pre-Clinical Trials
3. Later Stage VC 08-Jan-2023 Completed Pre-Clinical Trials
2. Later Stage VC 26-May-2021 $1.98M $2.33M Completed Pre-Clinical Trials
1. Angel (individual) 28-May-2020 $345K $345K Completed Pre-Clinical Trials
To view Argonaute RNA’s complete valuation and funding history, request access »

Argonaute RNA Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preference Ordinary
Ordinary
Ordinary 280,000 $0.000082 $1.28 $1.28 1x $1.28 6.83%
To view Argonaute RNA’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Argonaute RNA Patents

  • 87

    Total Documents Applications and Grants

  • Total Patents Families

  • 22

    Granted

  • 19

    Pending

  • Expiring in next 12 mo

Argonaute RNA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202510735-D0 Linkers Pending 03-Jul-2025
GB-202415719-D0 Cancer therapy Pending 25-Oct-2024
GB-202415716-D0 Dual silencing Pending 25-Oct-2024
GB-2702002-A Gene silencing of cardiovascular genes Pending 25-Oct-2024
GB-2703042-A Gene silencing of cardiovascular genes Pending 25-Oct-2024 C12N15/113
To view Argonaute RNA’s complete patent history, request access »

Argonaute RNA Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Argonaute RNA Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Development Bank of Wales Growth/Expansion Minority
Empirical Ventures Venture Capital Minority
Bristol Private Equity Club Growth/Expansion Minority
CatSci PE-Backed Company Minority
Fink Family Office Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Argonaute RNA FAQs

  • When was Argonaute RNA founded?

    Argonaute RNA was founded in 2015.

  • Where is Argonaute RNA headquartered?

    Argonaute RNA is headquartered in Cardiff, United Kingdom.

  • What is the size of Argonaute RNA?

    Argonaute RNA has 8 total employees.

  • What industry is Argonaute RNA in?

    Argonaute RNA’s primary industry is Drug Discovery.

  • Is Argonaute RNA a private or public company?

    Argonaute RNA is a Private company.

  • What is Argonaute RNA’s current revenue?

    The current revenue for Argonaute RNA is .

  • How much funding has Argonaute RNA raised over time?

    Argonaute RNA has raised $7.98M.

  • Who are Argonaute RNA’s investors?

    Development Bank of Wales, Empirical Ventures, Bristol Private Equity Club, CatSci, and Fink Family Office are 5 of 9 investors who have invested in Argonaute RNA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process